To further examine the effects of the combination treatment on activation of Nrf2 and EGFR, human NSCLC H1299 cells with wild-type Keap1 were treated with TGF-β and hypoxia/reoxygenation. Here, KEAP1 is linked to non-small cell lung carcinoma.